Loading...
XNAS
CRMD
Market cap684mUSD
Jul 09, Last price  
8.67USD
1D
-1.81%
1Q
19.75%
Jan 2017
13.33%
IPO
-42.20%
Name

CorMedix Inc

Chart & Performance

D1W1MN
XNAS:CRMD chart
P/E
4.17
P/S
2.18
EPS
2.08
Div Yield, %
Shrs. gr., 5y
22.97%
Rev. gr., 5y
319.75%
Revenues
312m
+617.03%
000002,000189,274210,130224,105329,327429,797283,266239,231190,93665,408043,472,170311,709,000
Net income
163m
P
-8,996,745-8,121,455-10,905,236-6,711,273-3,425,682-9,133,098-20,453,427-18,187,529-24,643,627-33,009,914-26,829,630-16,433,074-22,027,683-28,210,226-29,701,705-46,339,227-17,930,020163,055,000
CFO
175m
P
-4,112,598-2,146,454-3,668,404-6,296,725-2,276,260-3,618,532-6,320,819-12,526,898-22,265,395-28,587,180-23,700,565-15,052,024-21,967,638-21,155,223-24,356,732-38,409,480-50,614,653175,046,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
IPO date
Mar 25, 2010
Employees
40
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT